PD-1 inhibition in gastric and esophageal cancer, hepatocellular carcinoma, and urothelial carcinoma
Adenocarcinoma of the stomach and gastroesophageal junction (GEJ) ranks fifth among the most common malignancies worldwide and is the third leading cause of cancer-related death in both sexes. Most patients are diagnosed at an advanced stage due to the asymptomatic early feature of the disease.